Publication Type : Journal Article
Publisher : IHJ Cardiovascular Case Reports (CVCR)
Source : IHJ Cardiovascular Case Reports (CVCR), Jan 2023 7;(1): 33-35. doi.org/10.1016/j.ihjccr.2023.03.001.
Url : https://www.sciencedirect.com/science/article/pii/S2468600X23000105
Keywords : Pregnancy, Pulmonary hypertension, Selexipag
Campus : Kochi
School : School of Medicine
Department : Paediatric Cardiology
Year : 2023
Abstract : Pregnancy poses a significant maternal and foetal risk in women with pulmonary arterial hypertension (PAH). With extremely limited treatment options available, we used Selexipag in addition to tadalafil in managing a pregnancy complicated by PAH. Selexipag may be a promising add-on therapy in this unique subset.
Cite this Research Publication : Sweta Mohanty, Janu Mangala Kanthi, Nitu Puthenveettil, Radhamany Kunjukutty, Shine Kumar. "Selexipag in pregnancy and pulmonary arterial hypertension," IHJ Cardiovascular Case Reports (CVCR), Jan 2023 7;(1): 33-35. doi.org/10.1016/j.ihjccr.2023.03.001.